Literature DB >> 9749579

Mitochondria in the etiology and pathogenesis of Parkinson's disease.

A H Schapira1, M Gu, J W Taanman, S J Tabrizi, T Seaton, M Cleeter, J M Cooper.   

Abstract

Mitochondria play a critical role in cellular energy metabolism. The identification of a respiratory chain defect in Parkinson's disease (PD) provides not only a direct link with toxin models of parkinsonism but also insight into the mechanisms involved in etiology and pathogenesis. The presence of the complex I deficiency in PD substantia nigra and platelets suggests the involvement of a systemic cause. Genomic transplantation studies have been undertaken that involve the transfer to a novel nuclear background of mitochondrial DNA (mtDNA) from PD patients with a complex I defect, followed by both mixed and clonal expansion of the resulting cybrids. The mixed cybrids with the PD mtDNA expressed the complex I defect present in the original PD donor platelets. Clonal expansion of one such mixed cybrid culture produced a spectrum of clones with complex I and complex IV activities, ranging from severe deficiency to normal range, a pattern typical of a heteroplasmic mtDNA mutation. Histochemical, immunohistochemical, and functional assessments of delta psi(m) all showed a pattern in the PD clones typical of that produced by a mtDNA mutation. Patients with focal dystonia and a platelet complex I defect were used as disease controls for the cybrid studies. The mitochondrial abnormality was eradicated by transfer of dystonia mtDNA to a control nuclear background in both mixed and clonal cybrids, with no evidence of clonal heterogeneity. These results help to validate our findings in the PD patients and suggest that the complex I deficiency in dystonia is not due to an abnormality of mtDNA. We hypothesize that the mtDNA defect alone may be the cause of PD in a proportion of patients and may contribute to pathogenesis in others. Identification of the mtDNA genotype responsible for PD may allow the testing of neuroprotective strategies in appropriate patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749579     DOI: 10.1002/ana.410440714

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

Review 1.  Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death.

Authors:  M R Duchen
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

2.  Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

Authors:  V Viswanath; Y Wu; R Boonplueang; S Chen; F F Stevenson; F Yantiri; L Yang; M F Beal; J K Andersen
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 3.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

5.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

6.  Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker.

Authors:  Ramesh C Juyal; Mitashree Das; Sohan Punia; Madhuri Behari; Geetika Nainwal; Sumit Singh; Pazhayannur V Swaminath; Shyla T Govindappa; Sachi Jayaram; Uday B Muthane; B K Thelma
Journal:  Neurogenetics       Date:  2006-07-01       Impact factor: 2.660

7.  Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

Authors:  Paula M Keeney; Caitlin K Quigley; Lisa D Dunham; Christina M Papageorge; Shilpa Iyer; Ravindar R Thomas; Kathleen M Schwarz; Patricia A Trimmer; Shaharyar M Khan; Francisco R Portell; Kristen E Bergquist; James P Bennett
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

8.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 9.  Science, medicine, and the future: Parkinson's disease.

Authors:  A H Schapira
Journal:  BMJ       Date:  1999-01-30

Review 10.  Mouse models of mitochondrial complex I dysfunction.

Authors:  Michael H Irwin; Kodeeswaran Parameshwaran; Carl A Pinkert
Journal:  Int J Biochem Cell Biol       Date:  2012-08-10       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.